---
title: Welcome to CHI
description: Cambridge Healthcare Innovations (CHI) is a company that invents and develops DPI technology for the world's pharmaceutical industry.
---
[Skip to content](https://chi.uk/home#main-content)
Close
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
SEARCH
[Contact us](https://chi.uk/about-us?hsLang=en#Contact)
[](https://chi.uk/home)
- [ABOUT](https://chi.uk/about-us)
- [Why work with us](https://chi.uk/about-us#Work-with-us)
- [Our values](https://chi.uk/about-us#Values)
- [The team](https://chi.uk/about-us#Meet-the-team)
- [Where to find us](https://chi.uk/about-us#Contact)
- [PRODUCTS](https://chi.uk/products)
- [Quattrii](https://chi.uk/products#Quattrii)
- [Aeolus](https://chi.uk/products#Aeolus)
- [Occorix](https://chi.uk/products#Occorix)
- [THE SCIENCE](https://chi.uk/the-science)
- [VACANCIES](https://chi.uk/vacancies)
- [BLOG](https://chi.uk/chi-blog)
[Contact us](https://chi.uk/about-us?hsLang=en#Contact)
# We areCambridge Healthcare Innovations
We are empowering a new era for respiratory medicine through the development of novel DPI platforms.
## Our DPI platforms
Covering fill masses of 1 mg to up to 150 mg, our novel inhaler engines can be used for new therapy areas that would benefit from direct lung delivery, or to replace existing inhalers and improve patient outcomes.
[ A blister-based DPI engine that is designed to deliver high payloads of up to 150 mg. Available in both API-only and carrier-based configurations. Read More](https://chi.uk/products?hsLang=en#Quattrii)[ A blister-based DPI engine that features a novel fluidic pressure amplifier that dramatically increases the effective lung power available from the patient. Designed for payloads of between 5 – 50 mg. Read More](https://chi.uk/products?hsLang=en#Aeolus)[ A blister-based active DPI that uses a novel blister design and aerosolisation engine to deliver up to 5 mg of pure API to the patient’s deep lung. Read More](https://chi.uk/products?hsLang=en#Occorix)
## Patient benefits
Our primary driver is to improve patient outcomes, whether that is saving lives, improving health, or reducing pain and discomfort. But how?
- By making respiratory drug delivery suitable for a wide range of conditions
- By ensuring the effective delivery of API to the target region of the patient’s lung
- By delivering consistent and reliable performance
- By making inhalers easy to use
- By minimising throat and mouth deposition (and therefore side effects or discomfort)
- By making inhalers suitable to use across a range of patient cohorts.
## Pharmaco benefits
The drug development process is complex and costly. Our DPI platforms make it faster, easier and cheaper for pharmaceutical companies to bring respirable drugs to market by offering:
- Platform technology that opens up respiratory drug delivery to many more therapy areas and drugs
- Our DPI engines can be used during drug discovery and scaled up through clinical trials to market approval, ensuring a consistent platform throughout and reducing the statistical burden
- Engines that can be fine-tuned to specific formulations
- Quattrii and Aeolus can be used for API-only or carrier-based formulations
- All of our DPI engines are designed to be suitable for a wide range of patient profiles.
[Learn more about us](https://chi.uk/about-us?hsLang=en)
## On the blog
Check out what we have been up to in our latest blog posts.
[All blog posts](https://chi.uk/chi-blog?hsLang=en)
### [Different Inspiratory Profiles, Same Fine Particle Dose](https://chi.uk/chi-blog/different-inspiratory-profiles-same-fine-particle-dose?hsLang=en)
### [Protecting the Molecule Before the Patient Ever Inhales](https://chi.uk/chi-blog/protecting-the-molecule-before-the-patient-ever-inhales?hsLang=en)
### [High-Dose Inhalation Should Not Mean Multiple Inhalations](https://chi.uk/chi-blog/high-dose-inhalation-should-not-mean-multiple-inhalations?hsLang=en)
### [Carrier-Free Powders Need a Different Kind of DPI](https://chi.uk/chi-blog/carrier-free-powders-need-a-different-kind-of-dpi?hsLang=en)
All rights reserved, Cambridge Healthcare Innovations Ltd 2026
- [Privacy policy](https://chi.uk/policies)
- Registered in England & Wales (GB11540827)
- [329 Cambridge Science Park, Cambridge CB4 0WG, UK](https://chi.uk/about-us#Contact)
```json
{
"@context" : "https://schema.org",
"@type" : "Organization",
"knowsLanguage" : "en",
"logo" : {
"@type" : "ImageObject",
"url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg"
},
"name" : "",
"url" : "https://chi.uk/home"
}
```